Stock 6990 SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Equities

6990

CNE1000062J1

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:03 2024-05-23 am EDT 		5-day change 1st Jan Change
174.3 HKD -3.70% Intraday chart for Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. +0.87% +69.39%
May. 08 Sichuan Kelun-biotech Biopharmaceutical to Place 3.6 Million Shares; Inks Subscription Deal for 4.4 Million Shares MT
May. 06 Kelun-Biotech's Lung Cancer Drug Advances to Phase 2 Trials in US; Shares Up 8% MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Sichuan Kelun-biotech Biopharmaceutical to Place 3.6 Million Shares; Inks Subscription Deal for 4.4 Million Shares
Kelun-Biotech's Lung Cancer Drug Advances to Phase 2 Trials in US; Shares Up 8%
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces Study Results for Core Product Scituzumab Turumotecan (SAC-TMT) at AACR Annual Meeting 2024
Kelun-Biotech Shrinks Loss by 7% in 2023
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
China Grants Breakthrough Therapy Designation for Kelun-Biotech's Breast Cancer Treatment
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces Its Core Product SKB264 (MK-2870) Granted Breakthrough Therapy Designation for First-Line Treatment of Unresectable Locally Advanced, Recurring or Metastatic Pd-L1 Negative Tnbc by the National Medical Products Administration
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces Key Product A400 Granted Fast Track Designation by the US Food and Drug Administration
Kelun-Biotech Shares Start Trading in Shanghai's Southbound Stock Connect
Kelun-Biotech Licensee Starts Phase 3 Trials for Cancer Treatment; Shares Rise 5%
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces Collaboration with Merck Sharp & Dohme LLC
Kelun-Biotech Chosen as Constituent Stock of Hang Seng Indexes; Shares Fall 3%
Kelun-Biotech Controlling Shareholder Ups Stake; Shares Rise 4%
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces New Drug Application for Core Product SKB264 (MK-2870) Accepts by the National Medical Products Administration
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. to Present the Updated Efficacy and Safety Results from Core Product
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Provides Update on Collaboration with Merck Sharp & Dohme LLC
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces Abstract for Oral Presentation of the Study Results from Core Product SKB264 (MK-2870) Published on the Website of the 2023 ESMO Congress
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Enters into an Exclusive License Agreement with the Affiliated Hospital of Southwest Medical University
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces National Medical Products Administration Accepts Drug Application for Key Product A140 Solution for Infusion
Sichuan Kelun Pharma to Start License Application Process For New Cancer Drug
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 6990 Stock
  4. News Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
  5. Other languages